Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

Valneva (NASDAQ:VALN – Free Report) had its target price trimmed by HC Wainwright from $18.00 to $17.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage ...

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

Valneva has met its revenue growth target for 2024, fending off slower-than-expected sales for the chikungunya vaccine Ixchiq. The French vaccine specialist posted total revenues of €169.6m ($ ...

Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 ...

H.C. Wainwright lowered the firm’s price target on Valneva (VALN) to $17 from $18 and keeps a Buy rating on the shares following the Q4 report.

More information is available at www.valneva.com. This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business ...

Ratings for Valneva (NASDAQ:VALN) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings ...

Valneva expects further sales growth this year after it posted higher revenue in 2024.

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business partnerships and the progress, timing, results and completion of ...